Edwards Lifesciences (NYSE:EW) Announces Quarterly Earnings Results

Edwards Lifesciences (NYSE:EW) posted its earnings results on Thursday. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04, FiscalAI reports. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the firm earned $0.67 EPS. The business’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences updated its Q3 2026 guidance to 0.710-0.770 EPS and its FY 2026 guidance to 2.950-3.050 EPS.

Here are the key takeaways from Edwards Lifesciences’ conference call:

• Edwards reported second-quarter sales growth of 12.5% to $1.74 billion, topping expectations and reflecting strength across all product groups and regions.
• Management raised full-year 2026 guidance for total company sales to 10%-11%, TAVR sales to 8%-9%, and TMTT revenue to $760 million-$780 million, while reaffirming adjusted EPS of $2.95-$3.05.
• TAVR delivered stronger-than-expected sales of $1.3 billion, with management citing continued SAPIEN adoption, stable pricing, favorable clinical data, and support from competitor exit dynamics. The company also highlighted first patients treated with the next-gen SAPIEN X4-S and expects the final CMS NCD policy in September.
• TMTT was a major growth driver, with sales up 44.8% year over year to $195.9 million as PASCAL, EVOQUE, and SAPIEN M3 all contributed. Edwards expects additional catalysts from next-gen PASCAL approvals, U.S. tricuspid launch, and broader EVOQUE and M3 scaling.
• Management also pointed to a strong surgical business, with sales up 5% and new evidence supporting RESILIA durability, plus U.S. approval of ECLIPTIS. However, the call emphasized that U.S. tax changes and FX headwinds will pressure margins and raise the effective tax rate near the high end of guidance.

Edwards Lifesciences Stock Down 1.4%

Shares of NYSE:EW opened at $82.67 on Friday. The company has a market capitalization of $47.60 billion, a price-to-earnings ratio of 47.51, a PEG ratio of 2.10 and a beta of 0.86. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29. The business has a 50-day moving average price of $87.73 and a 200 day moving average price of $83.88. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Insider Buying and Selling at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 45,577 shares of company stock valued at $3,855,527 over the last 90 days. 0.31% of the stock is owned by insiders.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently made changes to their positions in EW. Kemnay Advisory Services Inc. bought a new position in Edwards Lifesciences during the 4th quarter worth approximately $27,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the third quarter worth $25,000. Rakuten Securities Inc. raised its holdings in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Kelleher Financial Advisors bought a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $50,000. Finally, Chapman Financial Group LLC bought a new stake in Edwards Lifesciences in the 2nd quarter valued at about $63,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. BTIG Research increased their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $101.00 target price on the stock in a research report on Friday. Royal Bank Of Canada lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Friday. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.55.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.